New hope for tough brain tumors: experimental drug JZP3507 enters trial

NCT ID NCT07533942

Recruiting now Disease control Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tests an oral drug called JZP3507 (ONC206) in 30 adults with recurrent grade 2 or 3 meningioma, a type of brain tumor. Participants take the drug three days a week in 28-day cycles. The main goal is to see if the drug can shrink tumors, with safety and response duration also tracked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JZP3507 (also called ONC206), an oral drug
What this could lead to: If successful, this could offer a new treatment option for people with recurrent meningioma who have run out of standard therapies.
What could go wrong: This is an early Phase 2 trial with only 30 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

grade II meningioma grade III meningioma meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENINGIOMA

Contacts and locations

Locations

Louisiana State University
NOT_YET_RECRUITING

New Orleans, Louisiana, 70112, United States
Mass General
NOT_YET_RECRUITING

Boston, Massachusetts, 02114, United States
NYU- Langone Health
RECRUITING

New York, New York, 10016, United States
Sutter Health
NOT_YET_RECRUITING

San Francisco, California, 94109, United States
University of Utah - Huntsman Cancer Institute
NOT_YET_RECRUITING

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.